Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Terminated × isatuximab × Clear all

Phase

Phase 1/2 3 Phase 2 2 Phase 1 2 Phase EARLY_PHASE1 1 Phase 3 1

Status

Active not recruiting 4 Completed 3 Terminated 1 Recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Multiple Myeloma 1

Interventions

Cisplatin 50 Carboplatin 44 Radiotherapy 41 Paclitaxel 40 Docetaxel 37 Gemcitabine 33 Cyclophosphamide 32 Rituximab 27 Fluorouracil 26 Doxorubicin 24 Dexamethasone 24 Capecitabine 24 Prednisone 20 Bevacizumab 19 Oxaliplatin 17 Leucovorin 17 Vincristine 15 Etoposide 15 Cytarabine 15 Pemetrexed 13 Drug Therapy 13 pembrolizumab 12 Zoledronic Acid 12 Radiosurgery 12 Irinotecan 12 Imatinib Mesylate 12 Filgrastim 12 Erlotinib Hydrochloride 11 Surgical Procedures, Operative 10 Standard of Care 10

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05675319 2026-01-05

AlloRelapseMM

Universitätsklinikum Hamburg-Eppendorf

Phase 3 Terminated

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡